"The US healthcare system’s focus on activity rather than value for money was behind the demise of Proteus Digital Health and its “digital pill”, which measured whether schizophrenia patients took their meds, according to the company’s former CEO.
At the Frontiers Health conference Andrew Thompson spoke to pharmaphorum’s web editor Catherine Longworth about lessons that can be learned from the company’s troubled attempt to market the technology.
Together with Japan’s Otsuka Pharmaceuticals, the company produced the ground-breaking smart pill Abilify Mycite (aripiprazole).
But the partnership ran into trouble after poor uptake by payers in the US and an ill-fated fundraiser.
After disappointing sales, Proteus filed for bankruptcy earlier this year and in September, Otsuka ended up buying what was left of Proteus for $20 million.
Although Novartis was reportedly also interested in the company’s technology, it was a huge fall from grace for Proteus Digital Health which was once valued at $1.5 billion..."
Lire la suite
Former CEO of Proteus reflects on the dramatic fall of 'digital pill' unicorn -
pharmaphorum, 16/11/2020
Partagé par :
Beesens TEAM

Informations liées
Thématiques
Modèles économiques
Thérapies digitales
Structures
Proteus
Incroyable ! Ces robots remplacent déjà des humains en chirurgie
OBJETCONNECTE,
Partagé par : Seddik Touaoula
Sommet IA : L'État présente les résultats des 35 défis "Convergence IA" de France 2030
L'USINE DIGITALE,
Partagé par : Seddik Touaoula
TME Pharma annonce sa collaboration avec aimed analytics pour la découverte et l’optimisation de médicaments par l’IA
MYPHARMA-EDITIONS,
Partagé par : Seddik Touaoula